Doctors about the transfer factor
The transfer factor prolongs our life and gives us back our youth.
Human immunity reaches its maximum by the age of 20, and then begins to decline.
First of all, the central organ of the immune system – the thymus gland (thymus) – atrophies. This leads to a noticeable decrease in the activity of cells of the immune system by the age of 30-40. And most importantly, the regulation and control of immune cells is significantly reduced, the number of autoimmune reactions increases, i.e. immunity “goes crazy” and begins to “beat on its own.” This, according to gerontologists, is the main reason for the rapid aging of the body.
Transfer factor is able to stop this process, giving the immune cells the necessary information, stopping autoimmune reactions. As a result of many years of research, Professor Alexei Chizhov has shown that the use of TF rejuvenates the body by an average of 6 years in just 6 weeks!
“… We actually received a basic agent that has no analogues, which can change the quality of life and significantly reduce biological age – this is Transfer Factors. The drug showed a decrease in biomarkers of aging for 42 days, by 6-8 years. ”
Patent RU 2 536 292 (13) C1
Vorobiev Anatoly Andreevich Honored Scientist of the Russian Federation, Academician of the Russian Academy of Medical Sciences, Doctor of Medicine sciences, professor head. Department of Immunology, Microbiology, Virology of the Academy. THEM. Sechenov
“The transfer factor combines inducer, suppressor and antigen-specific fractions of immunity, therefore only it fully has the right to be called an immunomodulator.
No other similar product contains all three fractions. ”
Monakhov Boris Vasilievich, Doctor of Medical Sciences, Professor, Member of the European Society of Medical Oncology (ESMO). ) Oncologist of the highest category, full member of the European Association of Oncologists
He has 5 years of experience in the use of transfer factors in patients with advanced forms of cancer, when all modern methods of treatment have been completely exhausted. In none of the cases was the progression of the malignant process noted.
Richard Bennett, Ph.D., 4Life Research Advisory Board Member